A modeling study projected that HPV vaccination programs for adults aged 27 to 45 years could benefit subgroups at higher risk for HPV, but overall, the approach is more costly and less effective than vaccinating younger people.
A modeling study projected that HPV vaccination programs for adults aged 27 to 45 years could benefit subgroups at higher risk for HPV, but overall, the approach is more costly and less effective than vaccinating younger people.